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Background: The association between inﬂuenza vaccination and implantable cardiac deﬁbrillator (ICD)
therapies during inﬂuenza season is not known and is described in this study. Understanding this
association is important since reduction in ICD therapies during inﬂuenza season via use of inﬂuenza
vaccination would beneﬁt patients physically and psychologically.
Methods: Patients presenting to the Sunnybrook Health Sciences Center ICD clinic between September
1st, 2011 and November 31st, 2011 were asked to complete a survey evaluating their use of the inﬂuenza
vaccine. The number of patients with any ICD therapy and the total number of ICD therapies in the six
months before and the three months during the 2010–2011 inﬂuenza season were determined. Poisson
regression analysis was employed to assess differences in the average number of ICD therapies received
during the inﬂuenza season based on vaccine status (vaccinated vs. unvaccinated). The analysis was
repeated after limiting the cohort to patients with a left ventricular ejection fraction r35%.
Results: A total of 229 patients completed the survey, 78% of whom received the inﬂuenza vaccine. Four
patients had more than one ICD shock during the study period. Electrical storm was rare (n¼2). A trend
toward more ICD therapies (unadjusted incident rate ratio (IRR)¼3.2; P¼0.07) and appropriate ICD
shocks (unadjusted IRR¼9.0; P¼0.17) was noted for unvaccinated compared to vaccinated patients. This
association persisted when analysis was limited to patients with a left ventricular ejection fraction r35%
(all ICD therapies: unadjusted IRR¼5.8; P¼0.045; adjusted IRR¼2.6; P¼0.33). No patient who received
the inﬂuenza vaccine, and had a reduced ejection fraction, received an approprite ICD shock during
inﬂuenza season (unadjusted Po0.002).
Conclusion: A trend toward more ICD therapies during inﬂuenza season was observed in patients who
did not receive the inﬂuenza vaccine compared to those who did. The association was stronger in
patients who received appropriate ICD shocks and in patients with left ventricular systolic dysfunction.
Further work to conﬁrm these ﬁndings is recommended.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
The association between inﬂuenza-like illness and adverse
cardiac events has been reported in several observational studies
[1,2], prompting the American Heart Association and Canadian
Cardiovascular Society to recommend annual inﬂuenza vaccina-
tion for patients with cardiac disease [3,4]. However, there has
been no study on the association between inﬂuenza vaccination
and cardiac arrhythmia, an underappreciated contributor of
cardiac morbidity and mortality. In this exploratory retrospective
study of 229 patients, we assessed the association between
inﬂuenza vaccination and implantable cardioverter deﬁbrillator
(ICD) therapies in the six months before and the three months
during the 2010–2011 inﬂuenza season.
2. Materials and methods
All patients with an ICD presenting for routine follow up at the
Sunnybrook Health Sciences Center ICD clinic, Toronto, Canada
between September 1st and November 30th, 2011 were asked to
participate in a survey assessing their use of the inﬂuenza
vaccination in the previous inﬂuenza season.
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Patient demographics, co-morbidities, and medication use were
ascertained from responses to survey questions and a review of
each patient's hospital chart. Each patient's ICD chart was reviewed
to conﬁrm the incidence of any ICD therapy (appropriate and
inappropriate shock or antitachycardia pacing) for an arrhythmic
event between June 1st, 2010 and March 1st, 2011. Inappropriate
ICD therapies secondary to lead or device malfunctions were
excluded, as they do not reﬂect arrhythmic events. The type of each
ICD therapy was adjudicated by two individuals (R.K. and S.M.S.).
December 1st, 2010–March 1st, 2011 was considered inﬂuenza
season, consistent with the peak of inﬂuenza season in Canada [5],
whereas June 1st, 2010–November 30th, 2010 was deemed “pre”-
inﬂuenza season. Of note, a good match between the inﬂuenza
vaccine and globally circulating inﬂuenza strains was noted during
this inﬂuenza season [6].
Patients were divided into two groups: those that received the
inﬂuenza vaccine and those that did not. Patient characteristics for
each group were reported as proportions, mean7standard devia-
tion or median with range where appropriate. Student's t-, Fisher's
exact, and Wilcoxon Rank-Sum tests were used to assess differ-
ences between the two groups.
The number of vaccinated or unvaccinated individuals receiv-
ing any ICD therapy (deﬁned as appropriate shock or antitachy-
cardia pacing for ventricular arrhythmias or inappropriate shock
or antitachycardia pacing for supraventricular arrhythmias) or any
appropriate ICD shock during the “pre”-inﬂuenza season (deﬁned
as the two 3 month periods preceding inﬂuenza season) and
during the inﬂuenza season (3 month period) was determined.
Any ICD therapy was considered to be reﬂective of the total
arrhythmia burden, and appropriate ICD shock was considered to
be reﬂective of the malignant ventricular arrhythmia burden.
Possible endpoints that may differ between vaccinated vs.
unvaccinated individuals were considered to be a reduction in
the number of vaccinated individuals receiving any ICD therapy
compared to unvaccinated individuals or a reduction in the total
number of arrhythmic events requiring ICD therapies in vaccinated
individuals, the latter of which accounts for clustering of arrhyth-
mia during the winter months [7]. A binomial test for proportions
was performed to assess differences in the total number of ICD
therapies between the groups during “pre”- and inﬂuenza season.
The “pre”-inﬂuenza season was divided into two 3 month periods
for comparison with the 3 month inﬂuenza period. Poisson
regression analysis [8] was employed to assess differences
between groups in the number of ICD therapies received during
inﬂuenza season. The analysis was repeated for appropriate ICD
shocks during inﬂuenza season. Results were reported as an
incident rate ratio (IRR) comparing the incidence of ICD therapies
in unvaccinated vs. vaccinated patients.
Since the patient cohort in this study was small, thereby
impacting the validity of multivariate analysis, our primary eva-
luation of ICD therapy incidence was unadjusted for differences
between the two study groups with regard to factors known to
impact cardiac arrhythmia, such as patient age, co-morbidity, or
history of ventricular arrhythmias. Secondary analyses adjusted for
these factors. Finally, when comparing the number of ICD thera-
pies during inﬂuenza season between patients who were or were
not vaccinated, an adjustment was made for the number of ICD
therapies received in the “pre”-inﬂuenza period. We repeated the
above analysis after restricting the cohort to those with a left
ventricular ejection fraction r35% to understand the impact of
inﬂuenza vaccination on all ICD therapies and appropriate ICD
shocks in patients with left ventricular systolic dysfunction.
For all analyses, a P-valueo0.05 was considered statistically
signiﬁcant. Statistical analyses were carried out using SAS version
9.3 (SAS Institute, Cary, NC). Ethical approval for this study was
obtained from the Sunnybrook Health Sciences Center Research
Ethics Board (Date of approval August 26th, 2011; Approval
number: 258-2011).
3. Results
A total of 229 patients completed the survey, representing 44% of
all ICD patients presenting to the Sunnybrook Health Sciences Center
ICD clinic during the study period, of which 78% reported receiving the
inﬂuenza vaccine. Table 1 summarizes the characteristics of patients
who did and did not receive the inﬂuenza vaccine. Unvaccinated
individuals were younger, less likely to have had a family physician for
at least 5 years, and more likely to have received a primary prevention
ICD. No differences in co-morbidities, left ventricular systolic ejection
fraction, use of anti-arrhythmic drugs, or median household income,
a marker of socio-economic status [9], were noted between the two
groups.
The retrospective nature of the study allowed for complete
information on ICD therapies to be obtained for all patients during
the study period. Overall, 17% of the 229 patients in our cohort
received any ICD therapy during the 9-month study period. Two
patients had electrical storm during the study period – one patient
who received the inﬂuenza vaccine had electrical storm in the
“pre”-inﬂuenza season (4 discrete ventricular tachycardia episodes
in 24 h requiring antitachycardia pacing) and one unvaccinated
patient had electrical storm during inﬂuenza season (4 discrete
ventricular tachycardia episodes requiring 4 ICD shocks). Multiple
ICD therapies (Z2 appropriate or inappropriate ICD shocks or
antitachycardia pacing) were noted in 19 patients, including
4 unvaccinated patients. Multiple ICD shocks (Z2 appropriate or
Table 1
Patient characteristics.
Inﬂuenza vaccination status P-value
Vaccinated (N¼180) Not vaccinated (N¼49)
Age (SD) 71 (10) 65 (11) o0.005
Male % 87 79 0.3
Median neighborhood income CDN$ (interquartile range) 27,086 (22,982–32,004) 26,305 (22,012–32,606) 0.9
Maintain family physician45years % 85 71 0.03
Coronary artery disease % 67 67 1.0
Renal disease % 7 12 0.2
Diabetes % 33 31 0.7
Stroke % 16 6 0.1
Ejection fraction % (SD) 29 (10) 29 (10) 0.8
Primary prevention deﬁbrillator use % 76 86 0.04
Use of anti-arrhythmic drugs % 73 72 0.6
SD¼standard deviation; CDN$¼Canadian dollar.
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inappropriate ICD shocks) were observed in 4 patients, including
3 unvaccinated patients.
There was no signiﬁcant difference in the absolute number of
individuals receiving any ICD therapy or appropriate ICD shocks
when comparing the 3 segments of time (Fig. 1). A non-signiﬁcant
trend toward more appropriate ICD shocks was observed in
unvaccinated individuals (Fig. 1, grey bar graph).
The mean number of all ICD therapies and appropriate ICD
shocks during inﬂuenza season is shown in Fig. 2. A trend toward a
greater average number of ICD therapies received during inﬂuenza
season (inappropriate and appropriate ICD shocks and antitachy-
cardia pacing) was observed in unvaccinated patients compared to
vaccinated patients (unadjusted IRR¼3.2; P¼0.07). Similar ﬁnd-
ings were noted when analyzing only appropriate ICD shocks
(unadjusted IRR¼9.0; P¼0.17). The IRRs were not signiﬁcant after
adjusting for age, primary versus secondary prevention indication,
use of anti-arrhythmic drugs and the number of “pre”-inﬂuenza
season ICD therapies (All ICD therapies: adjusted IRR¼1.2;
P¼0.81; Appropriate ICD shocks: adjusted IRR¼0.31; P¼0.64).
When the analysis was limited to subjects with a left ventri-
cular ejection fraction r35% (Fig. 2), unvaccinated individuals
received a signiﬁcantly greater number of any ICD therapies during
inﬂuenza season than vaccinated individuals (unadjusted IRR¼5.8;
P¼0.045). However, signiﬁcance was not reached after adjusting
for factors known to impact cardiac arrhythmia (adjusted
IRR¼2.6; P¼0.31). Unvaccinated patients in this speciﬁc cohort
received a signiﬁcantly greater number of appropriate ICD shocks
(Po0.002) since no vaccinated patients with a left ventricular
ejection fraction o35% received an appropriate ICD shock during
the inﬂuenza season.
4. Discussion
An association between inﬂuenza vaccination and ICD thera-
pies was assessed in this single center, retrospective study. To our
knowledge this is the ﬁrst study to assess the impact of inﬂuenza
vaccination on ICD therapies. The data indicate a trend toward a
higher incidence of ICD therapies during inﬂuenza season in
unvaccinated compared to vaccinated patients, with greater trends
in patients receiving appropriate ICD shocks and in patients with
left ventricular systolic dysfunction. These ﬁndings are suggestive
of a beneﬁcial effect of inﬂuenza vaccination on the burden of
cardiac arrhythmia during inﬂuenza season.
An increased incidence of ventricular arrhythmias in winter
and spring has been described, although the mechanism is
unknown [7,10]. Non-arrhythmic cardiac events also increase in
winter, potentially related to acute inﬂuenza infection. Possible
mechanisms for increased cardiac events with inﬂuenza infection
include an increase in circulating clotting factors and inﬂamma-
tory cytokines, which may enhance thrombosis, induce endothelial
dysfunction, or inhibit vasodilation [10], all of which may result in
ischemia and heart failure, leading to arrhythmia. Prevention of
Fig. 1. Percentage of vaccinated and unvaccinated patients receiving implantable cardioverter deﬁbrillator (ICD) therapies (any and appropriate ICD shocks) in the “pre”- and
inﬂuenza seasons. Fluþ¼vaccined against inﬂuenza; Flu¼unvaccinated; All ICD therapies¼appropriate and inappropriate ICD shocks and antitachycardia pacing. The
“pre”-inﬂuenza season was divided into two three month periods for comparison with the three month inﬂuenza season. There were no signiﬁcant P-values for any
comparisons.
Fig. 2. Mean number of implantable cardioverter deﬁbrillator (ICD) therapies (any
and appropriate shocks) per vaccinated or unvaccinated patient during the
inﬂuenza season. Fluþ¼vaccinated against inﬂuenza; Flu¼unvaccinated; All
ICD therapies¼appropriate and inappropriate ICD shocks and antitachycardia
pacing. Unadjusted P-values reported.
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inﬂuenza infection may attenuate this cascade, thereby attenuat-
ing arrhythmia risk in winter.
The presence of an ICD allowed us to determine the precise
number of arrhythmic events. Our work suggests a trend toward a
higher cardiac arrhythmia burden, including malignant cardiac
arrhythmia requiring appropriate ICD therapies, during inﬂuenza
season in unvaccinated patients. Our ﬁndings suggest a potential
beneﬁt of inﬂuenza vaccination on cardiac arrhythmia burden. The
lack of statistical signiﬁcance in most of our ﬁndings likely reﬂects
the lack of power in our small, exploratory study. However, the
trend toward a beneﬁt of inﬂuenza vaccination for decreasing
the total number of ICD therapies and the number of appropriate
ICD shocks adds credibility to our hypothesis that inﬂuenza
vaccination reduces cardiac arrhythmia. Furthermore, the larger
trend observed in patients with left ventricular systolic dysfunc-
tion and, in particular, the larger trend observed when limiting the
analysis to appropriate ICD shocks, adds additional support to our
hypothesis.
The observed increase in the number of ICD therapies during
inﬂuenza season is consistent with prior reports describing
increased cardiac arrhythmia burden in winter [9], possibly
requiring a larger number of ICD therapies. Inﬂuenza vaccination
may attenuate this. The low incidence of electrical storms
observed in our study is likely a reﬂection of the small sample
size and milder inﬂuenza season in 2011. Given the larger trend
toward a beneﬁt of inﬂuenza vaccination when analyzing appro-
priate ICD therapies, we speculate that vaccination may reduce the
burden of electrical storm in ICD patients.
Our ﬁndings support the current Class I recommendations by
the American Heart Association and the Canadian Cardiovascular
Society for inﬂuenza vaccination in patients with heart failure.
There is currently little direct evidence supporting the beneﬁt of
inﬂuenza vaccination in heart failure patients and the recommen-
dation to vaccinate these patients is based on consensus opinion
or small studies [3,4]. Our exploratory study adds to existing
literature supporting the potential cardiac beneﬁts of inﬂuenza
vaccination in patients with stable cardiovascular disease. We
advocate for larger scale studies to better appreciate the magni-
tude of cardiac beneﬁt associated with inﬂuenza vaccination.
Our ﬁndings, particularly if conﬁrmed by other groups, should
be communicated to ICD patients to ensure their universal
inﬂuenza vaccination. Despite the current recommendations for
patients with heart failure to be vaccinated against inﬂuenza, over
20% of patients in our cohort did not receive the intervention. This
less than optimal vaccination rate in cardiac patients has also been
demonstrated by others [11]. The potential beneﬁts of a reduction
in cardiac arrhythmia suggested by our work, proven non-cardiac
beneﬁts of inﬂuenza vaccination in adult patients [12], and current
Class I recommendations by various Societies should prompt
consideration of the inﬂuenza vaccination rate as a performance
measure in cardiac electrophysiology.
This study has limitations. First, the sample size was small and
the event rate was low, reducing the power to detect statistically
signiﬁcant differences between the two groups. Second, we were
unable to assess differences between those who completed the
survey and those who did not; unmeasured differences between
survey responders and non-responders may have introduced bias
and compromised the generalizability of our ﬁndings. Third,
vaccination status was determined by survey. While this approach
may be subject to “recall” bias, it is considered the current gold
standard for ascertaining vaccination status [13]. Fourth, clinical
details such as hospitalization for a respiratory illness or serologic
evidence of acute inﬂuenza infection at the time of receipt of ICD
therapies were not available, thereby preventing us from further
commenting on the association between ICD therapies and acute
inﬂuenza infection. Finally, although we adjusted for other
predictors of ICD therapies, we cannot exclude a “healthy-user”
bias – that is this possibility that inherently healthier patients
chose to receive the inﬂuenza vaccine [14]. This possibility is well
known in retrospective studies evaluating use of the inﬂuenza
vaccine [15] and is unlikely to be overcome outside of a rando-
mized clinical trial, which is likely unethical given the current
Class I recommendations for use of this intervention.
5. Conclusion
In conclusion, the data suggest that inﬂuenza vaccination may
reduce the incidence of ICD therapies during inﬂuenza season,
particularly appropriate ICD therapies. The effect is more pro-
nounced in patients with left ventricular systolic dysfunction. We
suggest an additional, larger scale study on the beneﬁts of
inﬂuenza vaccination in this patient population to conﬁrm our
ﬁndings.
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